Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lorlatinib

FDA-approved product (tablet, oral), marketed as Lorbrena.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lorlatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Lymphoma
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lorlatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lorlatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib

    NCT07782359 · start 2026-10

    Registered record
    Registry ID
    NCT07782359
    Conditions
    Lung Cancer
    Interventions
    Tirzepatide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2030-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    InterventionTirzepatide
    PhasePhase 1
    Registry statusNot yet recruiting

  • Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

    NCT07750704 · start 2026-09

    Registered record
    Registry ID
    NCT07750704
    Conditions
    ALK Positive Non-small Cell Lung Cancer
    Interventions
    Lorlatinib; sacituzumab tirumotecan plus lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2030-03
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK Positive Non-small Cell Lung Cancer
    InterventionLorlatinib; sacituzumab tirumotecan plus lorlatinib
    PhasePhase 2
    Registry statusNot yet recruiting

  • Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC

    NCT07674524 · start 2026-08-01

    Registered record
    Registry ID
    NCT07674524
    Conditions
    Non-Small Cell Lung Cancer (NSCLC); Hyperlipidemia; ALK Gene Mutation; ALK-positive
    Interventions
    For Part A - Observational Cohort:; Part B: Intensive Lipid-Lowering Group; For Part B - Intensive Group
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2029-12-31
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer (NSCLC); Hyperlipidemia; ALK Gene Mutation; ALK-positive
    InterventionFor Part A - Observational Cohort:; Part B: Intensive Lipid-Lowering Group; For Part B - Intensive Group
    PhaseNot recorded
    Registry statusNot yet recruiting

  • AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

    NCT07617337 · start 2026-07-24

    Registered record
    Registry ID
    NCT07617337
    Conditions
    ALK Positive Non-small Cell Lung Cancer
    Interventions
    AQUA07; Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-07-24
    Completion
    2030-08-31
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK Positive Non-small Cell Lung Cancer
    InterventionAQUA07; Lorlatinib
    PhasePhase 1
    Registry statusRecruiting

  • OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy

    NCT07655583 · start 2026-05-27

    Registered record
    Registry ID
    NCT07655583
    Conditions
    Brain Metastasis; Stereotactic Radiosurgery; Resection; Systemic Therapy
    Interventions
    Systemic therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-05-27
    Completion
    2030-06-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Metastasis; Stereotactic Radiosurgery; Resection; Systemic Therapy
    InterventionSystemic therapy
    PhasePhase 1
    Registry statusRecruiting

  • A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

    NCT07567352 · start 2026-05-01

    Registered record
    Registry ID
    NCT07567352
    Conditions
    Non-Small-Cell Lung; ALK-positive Advanced NSCLC; ALK-positive Non-small-cell Lung Cancer; ALK-positive NSCLC
    Interventions
    lorlatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2026-05-01
    Completion
    2027-03-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small-Cell Lung; ALK-positive Advanced NSCLC; ALK-positive Non-small-cell Lung Cancer; ALK-positive NSCLC
    Interventionlorlatinib
    PhaseNot recorded
    Registry statusActive not recruiting

  • Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

    NCT07633626 · start 2026-03-10

    Registered record
    Registry ID
    NCT07633626
    Conditions
    Advanced ALK/ROS1-positive NSCLC; Carcinoma, Non-Small-Cell Lung (NSCLC); Lung Adenocarcinoma; ALK-positive Non-small Cell Lung Cancer (NSCLC); Cognitive Dysfunction; Depression
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-03-10
    Completion
    2027-11-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced ALK/ROS1-positive NSCLC; Carcinoma, Non-Small-Cell Lung (NSCLC); Lung Adenocarcinoma; ALK-positive Non-small Cell Lung Cancer (NSCLC) +2 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

    NCT07374614 · start 2026-01-31

    Registered record
    Registry ID
    NCT07374614
    Conditions
    Non-Small Cell Lung Cancer; ALK; Iruplinalkib; Lorlatinib; Real-world Study; Observational Study
    Interventions
    Iruplinalkib tablets
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-01-31
    Completion
    2028-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer; ALK; Iruplinalkib; Lorlatinib +2 more
    InterventionIruplinalkib tablets
    PhaseNot recorded
    Registry statusRecruiting

  • Lorlatinib in ROS1+ NSCLC With Brain Metastasis

    NCT07083687 · start 2025-08-15

    Registered record
    Registry ID
    NCT07083687
    Conditions
    Lung Cancer (NSCLC)
    Interventions
    Lorlatinib 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-08-15
    Completion
    2028-12-01
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer (NSCLC)
    InterventionLorlatinib 100 mg
    PhasePhase 2
    Registry statusNot yet recruiting

  • Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

    NCT06333899 · start 2025-08-03

    Registered record
    Registry ID
    NCT06333899
    Conditions
    High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Infant Type Hemispheric Glioma; Glioblastoma; Glioblastoma Multiforme; WHO Grade III Glioma; WHO Grade IV Glioma; Diffuse Midline Glioma, H3K27-altered
    Interventions
    Lorlatinib; Lorlatinib with chemotherapy1; Lorlatinib with chemotherapy 2; Lorlatinib post Radiation
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2025-08-03
    Completion
    2035-06-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Infant Type Hemispheric Glioma +5 more
    InterventionLorlatinib; Lorlatinib with chemotherapy1; Lorlatinib with chemotherapy 2; Lorlatinib post Radiation
    PhaseEarly phase 1
    Registry statusRecruiting

  • A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

    NCT06678555 · start 2025-07-04

    Registered record
    Registry ID
    NCT06678555
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Lorlatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2025-07-04
    Completion
    2026-04-14
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionLorlatinib
    PhaseNot recorded
    Registry statusCompleted

  • Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

    NCT06487078 · start 2025-01-20

    Registered record
    Registry ID
    NCT06487078
    Conditions
    ALK+ Non-Small-Cell Lung Carcinoma
    Interventions
    Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-01-20
    Completion
    2028-11-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK+ Non-Small-Cell Lung Carcinoma
    InterventionLorlatinib
    PhaseNot applicable
    Registry statusRecruiting

  • Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer

    NCT06682884 · start 2024-11-15

    Registered record
    Registry ID
    NCT06682884
    Conditions
    Neoadjuvant Non-Small Cell Lung Cancer
    Interventions
    Lorlatinib 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-11-15
    Completion
    2027-05-31
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoadjuvant Non-Small Cell Lung Cancer
    InterventionLorlatinib 100 mg
    PhasePhase 2
    Registry statusNot yet recruiting

  • Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC

    NCT06690541 · start 2024-11-10

    Registered record
    Registry ID
    NCT06690541
    Conditions
    Lung Cancer, Non-Small Cell
    Interventions
    Lorlatinib 100 mg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2024-11-10
    Completion
    2030-10-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer, Non-Small Cell
    InterventionLorlatinib 100 mg
    PhaseNot recorded
    Registry statusNot yet recruiting

  • The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study

    NCT06652555 · start 2024-10-30

    Registered record
    Registry ID
    NCT06652555
    Conditions
    ALK; NSCLC
    Interventions
    Group 1
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2024-10-30
    Completion
    2027-09-29
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK; NSCLC
    InterventionGroup 1
    PhaseNot recorded
    Registry statusNot yet recruiting